# Pharmacokinetics and Pharmacodynamics Study

> **NCT07074236** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C

## Interventions

- **DRUG:** QLC7401 injection
- **DRUG:** RBD7022 injection

## Key facts

- **NCT ID:** NCT07074236
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07074236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07074236, "Pharmacokinetics and Pharmacodynamics Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07074236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*